Abstract
Background: The overactive bladder syndrome is a common condition affecting ∼12% of men and women. It is extremely disturbing with a great impact on quality of life. Its treatment involves a combination of behavioural and pharmacological therapy. The latter includes antimuscarinic drugs such as tolterodine. Objective: To review the safety and efficacy of tolterodine in the treatment of overactive bladder in comparison with other available antimuscarinic agents. Methods: A Pubmed search was carried out differentiating randomised, clinical trials; longitudinal, retrospective studies, and metanalysis on the use of tolterodine for overactive bladder treatment. In the comparison with other antimuscarinic agents, only randomised, clinical trials were considered. Results/conclusion: Tolterodine is available as immediate- or extended-release formulations. It has been extensively evaluated with long-term, randomised trials for safety and efficacy showing a significant improvement in overactive bladder symptoms with an excellent tolerability profile.
| Original language | English |
|---|---|
| Pages (from-to) | 1249-1255 |
| Number of pages | 7 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 9 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - May 2008 |
Keywords
- Antimuscarinic agents
- Decrusor overacrivity
- Overactive bladder
- Tolterodine
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)